U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H27NO9.ClH
Molecular Weight 533.955
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IDARUBICIN HYDROCHLORIDE

SMILES

Cl.[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(C=CC=C5)C4=O)C(O)=C23)C(C)=O

InChI

InChIKey=JVHPTYWUBOQMBP-RVFAQHLVSA-N
InChI=1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10-,15-,16-,17-,21+,26-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C26H27NO9
Molecular Weight 497.4939
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Idarubicin is an antineoplastic in the anthracycline class.Idarubicin hydrochloride is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. The absence of a methoxy group at position 4 of the anthracycline structure gives the compound a high lipophilicity which results in an increased rate of cellular uptake compared with other anthracyclines.Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Idarubicin in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults.

Originator

Curator's Comment: # Pfizer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
IDAMYCIN

Approved Use

IDAMYCIN PFS Injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.7 ng/mL
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IDARUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
423.2 ng × h/mL
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IDARUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
38.8 h
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IDARUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
IDARUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (all grades, 3 patients)
Thrombocytopenia (all grades, 3 patients)
Mucositis (all grades, 3 patients)
Anorexia (all grades, 3 patients)
Diarrhea (all grades, 3 patients)
Vomiting (all grades, 2 patients)
Left ventricular systolic dysfunction (all grades, 2 patients)
Cardiac arrhythmia (all grades, 1 patient)
Rash (all grades, 2 patients)
Infection (all grades, 3 patients)
Sources:
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (50%)
Vomiting (50%)
Mucositis (20%)
Diarrhea (20%)
Alopecia (15%)
Anorexia (11%)
Sepsis (2%)
Hepatitis (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cardiac arrhythmia all grades, 1 patient
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Left ventricular systolic dysfunction all grades, 2 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Rash all grades, 2 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Vomiting all grades, 2 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Anorexia all grades, 3 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Diarrhea all grades, 3 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Infection all grades, 3 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Mucositis all grades, 3 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Neutropenia all grades, 3 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Thrombocytopenia all grades, 3 patients
18 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 18 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 18 mg/m2, 1 times / day
Co-administed with::
cytarabine(100 mg/m^2/day)
Sources:
unhealthy, 23-60
n = 3
Health Status: unhealthy
Condition: acute myeloid leukemia
Age Group: 23-60
Sex: M+F
Population Size: 3
Sources:
Anorexia 11%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Alopecia 15%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Hepatitis 2%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Sepsis 2%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Diarrhea 20%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Mucositis 20%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Nausea 50%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
Vomiting 50%
15 mg/m2 1 times / day multiple, oral
Dose: 15 mg/m2, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/m2, 1 times / day
Co-administed with::
metoclopramide(10 mg; 2/day)
Sources:
unhealthy, 66 years (range: 40-85 years)
n = 46
Health Status: unhealthy
Condition: non-Hodgkin's lymphoma
Age Group: 66 years (range: 40-85 years)
Population Size: 46
Sources:
PubMed

PubMed

TitleDatePubMed
High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study.
2001
Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
2001
Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy.
2001
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
2001 Apr
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
2001 Apr
Acute basophilic leukemia.
2001 Aug
Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
2001 Aug
Generation of reactive oxygen species is not involved in idarubicin-induced apoptosis in human leukaemic cells.
2001 Dec
Therapy-related myelodysplastic syndrome/acute myeloid leukemia M2 and translocation (8;21).
2001 Dec
Contribution of specific transport systems to anthracycline transport in tumor and normal cells.
2001 Dec
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
2001 Dec
Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay.
2001 Dec 1
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
2001 Dec 15
Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
2001 Feb 15
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
2001 Jan
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells.
2001 Jul
Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
2001 Jul
Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
2001 Jul
Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
2001 Jul
High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
2001 Jun
Severe hepatic injury associated with lipid formulations of amphotericin B.
2001 Mar 1
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
2001 May 15
Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia.
2001 Nov
And the sun keeps shining.
2001 Nov
Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study.
2001 Nov
Recent advances in the prevention of anthracycline cardiotoxicity in childhood.
2001 Nov
Anthracyclines: recent developments in their separation and quantitation.
2001 Nov 25
An adjustment for a post-randomization variable in the comparison of two treatments for survival.
2001 Nov 30
A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
2001 Oct
LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.
2001 Oct
High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study.
2001 Oct
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
2001 Oct 15
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
2001 Oct 15
Pharmacokinetics and toxicity of idarubicin in the rat.
2001 Oct-Dec
Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single institute.
2001 Sep
Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs.
2001 Sep
Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.
2001 Sep
A case of zygomycosis and invasive candidiasis involving the epiglottis and tongue in an immunocompromised patient.
2002
Differential antigenotoxic and cytoprotective effect of amifostine in idarubicin-treated mice.
2002
Automated differential counts in acute promyelocytic leukemia patients may be misleading.
2002 Apr
Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
2002 Apr 25
Diversity of the apoptotic response to chemotherapy in childhood leukemia.
2002 Feb
AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation.
2002 Feb
Retinoic acid syndrome: a case of massive lung consolidation.
2002 Feb
Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
2002 Feb
[Acute myelogenous leukemia associated with severe esophageal stricture after chemotherapy].
2002 Jan
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
2002 Jan
Effects of cytarabine and various anthracyclins on platelet activation: characterization of in vitro effects and their possible clinical relevance in acute myelogenous leukemia.
2002 Jan 1
Cell-based assays for identification of novel double-strand break-inducing agents.
2002 Jan 16
Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity.
2002 Mar
Patents

Sample Use Guides

For induction therapy in adult patients with AML the following dose schedule is recommended: Idarubicin 12 mg/m2 daily for 3 days by slow (10 to 15 min) intravenous injection in combination with cytarabine. The cytarabine may be given as 100 mg/m2 daily by continuous infusion for 7 days or as cytarabine 25 mg/m2 intravenous bolus followed by cytarabine 200 mg/m2 daily for 5 days continuous infusion. In patients with unequivocal evidence of leukemia after the first induction course, a second course may be administered. Administration of the second course should be delayed in patients who experience severe mucositis, until recovery from this toxicity has occurred, and a dose reduction of 25% is recommended. In patients with hepatic and/or renal impairment, a dose reduction of IDAMYCIN PFS should be considered. Idarubicin should not be administered if the bilirubin level exceeds 5 mg%
Route of Administration: Intravenous
Treatment of HL-60 cells with 1 uM Idarubicin for 2 h could not induce internucleosomal DNA fragmentation, however, a ladder of DNA fragment, characteristic of apoptosis, was observed after incubation for 4 h. After 10-h, extensive DNA degradation was observed. When HL-60 cells were incubated with different doses of Idarubicin for 8 h, the degree of DNA fragmentation increased at the higher concentration.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:15:40 GMT 2023
Edited
by admin
on Fri Dec 15 15:15:40 GMT 2023
Record UNII
5VV3MDU5IE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IDARUBICIN HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
IDAMYCIN
Brand Name English
IDARUBICIN HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
IDARUBICIN HYDROCHLORIDE [JAN]
Common Name English
IDARUBICIN HYDROCHLORIDE [VANDF]
Common Name English
IDARUBICIN HYDROCHLORIDE [USAN]
Common Name English
Idarubicin hydrochloride [WHO-DD]
Common Name English
IMI-30
Code English
1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE, HYDROCHLORIDE
Common Name English
5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXYHYDROCHLORIDE, (7S-CIS)-
Common Name English
IDARUBICIN HYDROCHLORIDE [USP-RS]
Common Name English
NSC-256439
Code English
IDARUBICIN HYDROCHLORIDE [MI]
Common Name English
IDARUBICIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
IDARUBICIN HCL
Common Name English
IMI 30
Code English
IDARUBICIN HYDROCHLORIDE [MART.]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 55890
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
NCI_THESAURUS C1594
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
FDA ORPHAN DRUG 29388
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
Code System Code Type Description
PUBCHEM
636362
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
EVMPD
SUB02635MIG
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
NSC
256439
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
MERCK INDEX
m6197
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY Merck Index
RXCUI
82124
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY RxNorm
DRUG BANK
DBSALT000341
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
SMS_ID
100000090504
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
USAN
X-47
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID0047797
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
ECHA (EC/EINECS)
260-990-7
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
CAS
57852-57-0
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
NCI_THESAURUS
C1587
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
FDA UNII
5VV3MDU5IE
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
RS_ITEM_NUM
1335701
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
DAILYMED
5VV3MDU5IE
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
ChEMBL
CHEMBL1117
Created by admin on Fri Dec 15 15:15:40 GMT 2023 , Edited by admin on Fri Dec 15 15:15:40 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY